BIOEMTECH

🎄 Christmas vibes at BIOEMTECH! 🎄 Last week was all about reflection, celebration and planning for the future! 📜 On Tuesday, we held our annual meeting, where the entire team came together to review the successes and milestones of 2024. It was inspiring to see the progress we've made and to discuss the goals for 2025. 🍸 On Thursday, our headquarters were filled with joy and laughter during our Christmas party. It was a wonderful opportunity to celebrate the holidays together and strengthen the bonds that make our team so special. ✨ Wishing you all a Happy New Year! ✨ #ChristmasSpirit #AnnualMeeting #TeamCelebration #MerryChristmas #HappyNewYear

🎯 An investigation into novel approaches to imaging. 🔬 @ BIOEMTECH, we are committed to ongoing innovation in the field of preclinical research for radiopharmaceuticals. With the advent of our new 3D imaging capability with the β-eye, we combine the speed 🏎️ and efficiency of 2D imaging with the detail 🤺 and depth of 3D. What implications does this have for researchers? 👩🔬   2D imaging allows us to detect critical features, such as a tumor in necrosis. However, the incorporation of 3D capabilities enables a further advancement in the resolution of structures and functions within vital organs, such as the heart 🫀 , thereby facilitating a more comprehensive understanding.   👁️ β-eye is the comprehensive tool that can support every step of your research, from tumour analysis to organ studies.   Images info 👇 2️⃣D imaging 18F-FDG - 1 hr post injection acquisition - 60 min dynamic scan - total injected dose 5,45MBq   3️⃣D imaging 18F-FDG - 1 hr post injection acquisition - 20 min dynamic scan - total injected dose 5,45MBq     #PreclinicalResearch, #Radiopharmaceuticals, #PET, #NuclearMedicine, #Oncology, #MolecularImaging, #CardiovascularResearch, #CardiacPETImaging

🪄 Flexibility that redefines preclinical radiopharmaceutical research!   At BIOEMTECH, we believe that technology should be driven by the evolving needs of research, rather than vice versa.   Our imaging systems for radiopharmaceutical research have proven their value in 2D imaging, offering speed 🏎️ and high sensitivity during the early stages of radiopharmaceutical development. However, recognising the need for greater flexibility, we have taken a step further.   The latest upgrade to the β-eye platform for #PET isotopes now also supports 3D imaging.   The capacity to transition between 2D and 3D imaging enables researchers to utilise the optimal tool for each phase of their study. 💡 2D imaging includes powerful resolution for early-stage research, great sensitivity, much faster procedures. 💡 3D imaging provides enhanced image reconstruction for more comprehensive analysis, allowing for a better assessment of more sophisticated models in oncology, cardiology, brain studies etc. This flexibility is not just an additional feature; it represents a novel approach to supporting research activities and facilitating more expedient and effective outcomes.   Are you ready to see the difference? Click here 👇 https://lnkd.in/g-bdpiKf or contact us for more information here 👇 info@bioemtech.com #radiopharmaceuticals, #RadioLigandTherapy, #Theranostics, #NuclearMedicine, #Oncology, #PreclinicalResearch, #PETimaging, #Tomography

🛬One week after returning from #TRP EU in Amsterdam🌷, some important aspects still linger in our thoughts. Especially, since we always try to bring back to the team @BIOEMTECH the key takeaways of worthwhile conferences and events and exploit the knowledge in our everyday practices. Our 3 main points 👇 1️⃣ #RLT research is governed by developers aiming at specific targets: PSMA (60), FAP (26), HER2 (20) & SSTR (12), however currently there are more than 80 different targets being studied while more than 100 developers are working on undisclosed targets. 2️⃣ Administered activity in clinical RLT is still governed by the activity used in #Iodine therapies, since most safety data are still derived from the past. #Dosimetry will play a significant role in adjusting this and avoiding underdosing patients just to be on the safe side. FDA is already open to such discussions, when enough supporting data are presented. 3️⃣ Phase 0 trials are essential to first image the biodistribution of a novel therapeutic compound, but using a low-dose therapeutic isotope is recommended over using a diagnostic analogue (e.g., low dose #Lu177, rather than #Ga68), since compounds’ conformation significantly changes with different isotopes. This will safely determine the real dosimetry data for upcoming Phase 1 dosing decisions. 🤔 Looking forward to seeing how this fast-paced field will evolve over the next months! #radiopharmaceuticals, #TRP, #RadioLigandTherapy, #Theranostics, #NuclearMedicine, #EANM, #Oncology, #PreclinicalResearch

👩🔬 Science Letter #️⃣ Νο3 @ BIOEMTECH’s Knowledge Hub 👉 https://lnkd.in/eJx84b-b 📆 This month we are pleased to publish an article by Ingrid Yao Mattisson, PhD on "Endometriosis – the invisible disease (even with imaging)". Ingrid obtained her PhD in experimental cardiovascular research studying autoimmune atherosclerosis in CVD and diabetes. She is currently Clinical Development Manager at Spago Nanomedical AB, where she ensures that clinical trials run smoothly. ✒️ Endometriosis is a #chronic, #inflammatory, #gynecologic condition affecting approximately 10% of individuals assigned female at birth, worldwide. The variety of symptoms and their different presentation lead to challenging identification of the condition, with an average wait for a diagnosis of 7-9 years globally. Today, endometriosis is diagnosed based on suspicion of disease concluded from the combination of symptoms, clinical findings, and several imaging modalities. For a definitive diagnosis, laparoscopy with confirmative histology is considered the gold standard. The clinical study SPAGOPIX-02 explored the contrast-enhancing efficacy of the manganese-based contrast agent Pegfosimer manganese in participants with suspected endometriosis. The study results show that the use of Pegfosimer manganese in MRI could lead to improved evaluation and pre-surgical staging of endometriosis extent.     #ScienceLetters, #KnowledgeHub, #endometriosis, #MRI, #GynecologicCondition, #imaging

Just returned from the 6th Targeted Radiopharmaceuticals Summit Europe in #Amsterdam🌷 ! Three days of intensive discussions between pharma, biotech, academia and clinicians across discovery, preclinical and clinical. 👩🔬 Discovery and development of novel targets, isotopes, translational aspects for first in human studies, dosimetry limitations and aspirations to properly dose patients where thoroughly presented and offered valuable insights. Listening to the leading companies of RLT field, sharing their experiences in a common discussion table, has been truly rewarding. The dynamic RLT field is aiming higher and higher and we BIOEMTECH are very proud being part of it! #radiopharmaceuticals, #TRP, #RadioLigandTherapy, #Theranostics, #NuclearMedicine, #EANM, #Oncology, #PreclinicalResearch

🌍 The #BIOEMTECH team will be in #Rome for the 4th International Congress on Inflammation and Infection Imaging! Come and meet us at our stand in the Hotel Marriot Courtyard Central Park and don't miss the BIOEMTECH presentation on "Micro-SPECT and micro-PET for small animal imaging" 🐁 ☢️ tomorrow at 15:50. We look forward to meeting you and discussing about how our #eyes 👁️🗨️ can be the tools that will elevate your imaging lab workflow. #imaging, #SPECT, #PET, #preclinical, #research, #inflammation, #infection

It's Christmas at BIOEMTECH headquarters!!! 🎉 💥 🎅 🍾 🎄 🌠

📣 Happy to announce that #BIOEMTECH's β-eye now offers the posibility for 3D imaging of PET isotopes. ☢️ 🐁 👨🔬 🧪 Learn more: https://lnkd.in/g-bdpiKf #molecularimaging, #preclinicalimaging, #radiopharmaceuticals, #theranostics, #drugdiscovery, #smallanimalimaging

☢️ #Technetium_99m (Tc-99m) is a metastable nuclear isomer of Technetium-99, which itself is an isotope of Technetium. It is employed in tens of millions of medical diagnostic procedures each year, making it the most widely used medical radioisotope globally. 🧪 Tc-99m was discovered by #Emilio_Segrè and #Glenn_T_Seaborg back in 1938. It is used as a radioactive tracer, and can be detected within the body by medical equipment such as gamma cameras. Its suitability for this role is well established due to its characteristics. It emits gamma rays with a photon energy of 140 keV and has a half-life equal to 6.0058 hours. ✅ The images presented here are from a study conducted on a healthy mouse that was injected intravenously with 500μCi (first image from the left) and 300μCi (two subsequent images). Images were obtained using #BIOEMTECH's γ-eye benchtop #SPECT tracer imaging system. We can observe the kinetics of the compound into the body of the mouse, as well as its accumulation at the liver and kidney. Further information on the γ-eye can be found here: 👉 https://lnkd.in/dk3BCzuC #radiopharmaceuticals, #nuclearmedicine, #radioactivetracers